Tema Oncology ETF Rating $41.83 0.00 (0.00%) As of 07/2/2026 03:59 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrendsBuy This Stock Tema Oncology ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.CANC Aggregate RatingModerate Buy 2.72Holdings in CANC have an aggregate rating of Moderate Buy based on 396 analyst ratings issued in the past year covering 23 companies (69.2% of the portfolio).CANC Aggregate Price Target$41.83High Prediction$41.83Average Prediction$41.83Low Prediction$41.83Holdings in CANC have an aggregate price target of $41.83 and a range of $41.83 to $41.83 covering 23 companies (69.2% of the portfolio).CANC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy2 Buy rating(s)Moderate Buy16 Moderate Buy rating(s)Hold5 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Oncology ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 23 CANC Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings6.59%RVMDRevolution Medicines$189.241.8894 of 5 stars3.00$135.39 -28.5%22News CoverageAnalyst ForecastInsider Trade5.05%LLYEli Lilly and Company$1,208.37-0.5%4.2852 of 5 stars2.87$1,235.07 2.2%30Trending NewsAnalyst UpgradeAnalyst Revision4.71%COGTCogent Biosciences$38.691.4534 of 5 stars2.86$43.73 13.0%144.00%LEGNLegend Biotech$29.913.1043 of 5 stars2.67$60.23 101.4%153.95%RHHBYRoche$53.041.8485 of 5 stars2.45$51.50 -2.9%11Analyst Revision3.47%MRKMerck & Co., Inc.$129.34-0.2%4.474 of 5 stars2.70$131.83 1.9%20Positive NewsAnalyst ForecastAnalyst RevisionGap Down3.35%BMYBristol Myers Squibb$58.05-0.1%4.5984 of 5 stars2.37$61.31 5.6%19Options VolumeAnalyst RevisionGap Down2.98%NUVLNuvalent$123.732.5294 of 5 stars2.15$127.73 3.2%20Short Interest Decrease2.97%JNJJohnson & Johnson$262.52-0.2%4.2635 of 5 stars2.74$256.70 -2.2%27Trending NewsGap Down2.96%ABBVAbbVie$260.88-0.1%4.0145 of 5 stars2.88$253.81 -2.7%25Analyst DowngradeAnalyst RevisionGap Down2.92%IMNMImmunome$23.612.9988 of 5 stars2.85$33.17 40.5%13News CoverageInsider TradeGap Down2.86%BBIOBridgeBio Pharma$77.192.7921 of 5 stars2.83$92.90 20.4%24Gap Down2.82%EXELExelixis$55.852.2844 of 5 stars2.35$47.60 -14.8%20Analyst ForecastOptions VolumeGap Down2.64%AMGNAmgen$374.153.918 of 5 stars2.43$355.50 -5.0%30Analyst ForecastGap Down2.64%IDYAIDEAYA Biosciences$37.653.1416 of 5 stars2.82$50.69 34.6%172.58%CGONCG Oncology$70.363.4049 of 5 stars2.71$81.73 16.2%14News CoveragePositive NewsGap Down2.31%GMABGenmab A/S$28.514.7856 of 5 stars2.75$38.21 34.0%12Analyst Forecast2.09%CELCCelcuity$107.952.8113 of 5 stars2.83$152.09 40.9%121.82%ZLABZai Lab$19.122.1132 of 5 stars2.57$40.00 109.2%7Insider Trade1.77%ONCBeOne Medicines$297.654.6703 of 5 stars2.93$390.00 31.0%15Analyst Forecast1.73%RLAYRelay Therapeutics$18.652.7823 of 5 stars3.00$23.30 24.9%11News CoverageInsider TradeGap Down1.58%ELVNEnliven Therapeutics$49.823.4153 of 5 stars2.86$67.83 36.2%7Analyst Forecast1.39%ZYMEZymeworks$26.313.1879 of 5 stars2.82$37.00 40.6%11Analyst ForecastGap Down This page (NASDAQ:CANC) was last updated on 7/5/2026 by MarketBeat.com Staff. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Oncology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Oncology ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CANC Stock Alerts